Role of Vitamin B6Deficiency in the Nitrogen Balance of Streptozotocin-Diabetic Rats

2007 ◽  
Vol 17 (5) ◽  
pp. 275-279
Author(s):  
Alceu Afonso Jordao ◽  
Fátima Liz dos Santos ◽  
Júlio Sérgio Marchini ◽  
Helio Vannucchi
Author(s):  
Marta Kuczeriszka ◽  
Leszek Dobrowolski ◽  
Agnieszka Walkowska ◽  
Iwona Baranowska ◽  
Joanna D. Sitek ◽  
...  

1988 ◽  
Vol 66 (1) ◽  
pp. 95-100 ◽  
Author(s):  
J. R. Dyer ◽  
C. E. Greenwood ◽  
M. I. McBurney

There are conflicting reports concerning the existence of severe hypermethioninemia in rats made diabetic with the pancreotoxin, streptozotocin. To determine whether this discrepancy is due to experimental differences in the severity of diabetes or the diet fed to the animals, streptozotocin-diabetic and control rats were fed either a casein-based semipurified diet or laboratory chow for 2 or 5 weeks. Plasma methionine concentrations were elevated six- to nine-fold after 2 weeks in the casein-fed diabetics compared with both their own controls and the chow-fed diabetics, respectively. Circulating methionine levels had declined sharply by 5 weeks in the casein-fed diabetics but were still more than twice those of the casein-fed control and chow-fed diabetic levels. Since methionine intakes were only 30% greater in the casein-fed diabetics than in the chow-fed diabetics, it is unlikely that this is the sole cause of the large differences in plasma methionine levels. The reason for the difference in circulating Met levels could not be explained on the basis of overall amino acid availability, since growth, nitrogen balance, and plasma large neutral amino acid profiles (excluding Met) were similar within control and diabetic groups fed the two diets.


1997 ◽  
Vol 32 (6) ◽  
pp. 726-733 ◽  
Author(s):  
Hitoshi Suzuki ◽  
Tooru Shimosegawa ◽  
Akihiko Satoh ◽  
Kenji Kimura ◽  
Shuichi Ohara ◽  
...  

2000 ◽  
Vol 279 (3) ◽  
pp. F573-F583 ◽  
Author(s):  
Radko Komers ◽  
Jessie N. Lindsley ◽  
Terry T. Oyama ◽  
Kristen M. Allison ◽  
Sharon Anderson

Nitric oxide (NO) has been implicated in the pathogenesis of renal hemodynamic changes in diabetes mellitus. However, the contribution of nitric oxide synthase (NOS) isoforms to intrarenal production of NO in diabetes remains unknown. To explore the role of NOS1 in the control of renal hemodynamics in diabetes, we assessed renal responses to inhibition of NOS1 with S-methyl-l-thiocitrulline (SMTC; administered into the abdominal aorta) in moderately hyperglycemic streptozotocin-diabetic rats (D) and their nondiabetic (C) and normoglycemic diabetic counterparts. The contribution of other NOS isoforms was also evaluated by assessing the responses to nonspecific NOS inhibition [ N G-nitro-l-arginine methyl ester (l-NAME)] in SMTC-treated diabetic rats. The number of NOS1-positive cells in macula densa of D and C kidneys was also evaluated by immunohistochemistry. D rats demonstrated elevated glomerular filtration rate (GFR) compared with C. SMTC (0.05 mg/kg) normalized GFR in D but had no effect in C. SMTC-induced reduction of renal plasma flow (RPF) was similar in C and D. Normoglycemic diabetic rats demonstrated blunted renal hemodynamic responses to NOS1 inhibition compared with hyperglycemic animals. Mean arterial pressure was stable in all groups. l-NAME induced a further decrease in RPF, but not in GFR, in D rats treated with SMTC. Immunohistochemistry revealed increased numbers of NOS1-positive cells in D. These observations suggest that NOS1-derived NO plays a major role in the pathogenesis of renal hemodynamic changes early in the course of diabetes. NOS1 appears to be the most important isoform in the generation of hemodynamically active NO in this condition.


2002 ◽  
Vol 435 (2-3) ◽  
pp. 187-194 ◽  
Author(s):  
Srinivas Gullapalli ◽  
Krishnamoorthy Gurumoorthy ◽  
Chaman Lal Kaul ◽  
Poduri Ramarao

1987 ◽  
Vol 35 (10) ◽  
pp. 1089-1093 ◽  
Author(s):  
F J Bedoya ◽  
J C Oberholtzer ◽  
F M Matschinsky

Glucose phosphorylation was studied in B-cell-enriched or in B-cell-depleted pancreatic islets from normal or streptozotocin-diabetic rats, respectively, using quantitative histochemical procedures. The data indicate that B-cell-enriched preparations from normal animals and whole islets from normals, diabetics, and insulin-treated diabetic animals have comparable glucokinase activities. Average maximum velocities were (mmol/kg dry tissue/hr) 134.1 +/- 7.3 for whole islets and 125.6 +/- 10.7 for the B-cell-enriched preparations from normal rats, 143.1 +/- 13.6 for B-cell-depleted islets from diabetic rats, and 124.4 +/- 10.7 for B-cell-depleted islets from insulin-treated diabetic animals. The Kmax for glucose of the enzyme in islets from untreated diabetic rats was 16 mM, comparable to the Kmax found for glucokinase from normal rat islets. Mannoheptulose, previously shown to be a competitive inhibitor of glucokinase from liver and normal islets, also inhibited glucokinase in B-cell-depleted islets from diabetic rats. The data indicate that glucokinase is not selectively located in the B-cell, as was previously assumed, but is also found in A- and/or D-cells of diabetic rats. This observation raises significant questions about the functional role of islet glucokinase under control and diabetic conditions.


Sign in / Sign up

Export Citation Format

Share Document